Infographic: Biosimilar Interchangeability

June 25, 2017
The Center for Biosimilars Staff

The Biologics Prescribers Collaborative released its comment letter to the FDA on the agency’s Considerations in Demonstrating Interchangeability, and made 5 key requests.

The Biologics Prescribers Collaborative released its comment letter to the FDA on the agency’s Considerations in Demonstrating Interchangeability, and made 5 key requests of the agency. Read more about the BPC's comments to the FDA here.

Related Content:

News

x